Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-07-09 DOI:10.1002/alz.70463

Alexandra Gogola, Xuemei Zeng, Lilcelia A. Williams, Theresa Chapple-McGruder, Anum Saeed, Brian J Lopresti, Beth Snitz, Dana Tudorascu, Davneet Minhas, Milos D. Ikonomovic, Julia Kofler, Cristy Matan, Tharick A. Pascoal, Howard Aizenstein, Henrik Zetterberg, Kaj Blennow, Oscar Lopez, Victor L Villemagne, Thomas K. Karikari, Ann D Cohen

{"title":"Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease","authors":"Alexandra Gogola, Xuemei Zeng, Lilcelia A. Williams, Theresa Chapple-McGruder, Anum Saeed, Brian J Lopresti, Beth Snitz, Dana Tudorascu, Davneet Minhas, Milos D. Ikonomovic, Julia Kofler, Cristy Matan, Tharick A. Pascoal, Howard Aizenstein, Henrik Zetterberg, Kaj Blennow, Oscar Lopez, Victor L Villemagne, Thomas K. Karikari, Ann D Cohen","doi":"10.1002/alz.70463","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Given the predominance of imaging and plasma biomarkers in Alzheimer's disease observational studies and clinical trials, it is critical to understand the differences between these biomarkers across racialized groups.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>A total of 260 older adults without dementia racialized as Black and/or African American (AA) and non-Hispanic white (NHW), ranging in age from 50 to 90 years (68.8 ± 9.1 years), were evaluated for differences in plasma amyloid-β (Aβ) 42/Aβ40, p-tau181, p-tau217, p-tau231, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) as well as Aβ positron emission tomography (PET) and magnetic resonance (MR) imaging-derived cortical thickness using Mann–Whitney U tests and analysis of covariance (ANCOVA).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Both Mann–Whitney tests and ANCOVA found significant differences between groups racialized as AA or NWH with respect to global <sup>11</sup>[C]-Pittsburgh Compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness values, p-tau181, and p-tau231 values (<i>p</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Racialization should be given more consideration in AD clinical research, particularly when biomarker results are used for inclusion or exclusion criteria for clinical trials and qualification in clinical practice.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Global <sup>11</sup>[C]-Pittsburgh compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness, p-tau181, and p-tau231 differed between groups</li>\n \n <li>Differences were unaffected by age, sex, apolipoprotein E *4 (APOE*4), education, and Mini-Mental State Examination (MMSE) score</li>\n \n <li>Racialization needs more consideration in Alzheimer's disease clinical research</li>\n \n <li>Additional work is needed to understand the sources of biomarker differences</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 7","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70463","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70463","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Given the predominance of imaging and plasma biomarkers in Alzheimer's disease observational studies and clinical trials, it is critical to understand the differences between these biomarkers across racialized groups.

METHODS

A total of 260 older adults without dementia racialized as Black and/or African American (AA) and non-Hispanic white (NHW), ranging in age from 50 to 90 years (68.8 ± 9.1 years), were evaluated for differences in plasma amyloid-β (Aβ) 42/Aβ40, p-tau181, p-tau217, p-tau231, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) as well as Aβ positron emission tomography (PET) and magnetic resonance (MR) imaging-derived cortical thickness using Mann–Whitney U tests and analysis of covariance (ANCOVA).

RESULTS

Both Mann–Whitney tests and ANCOVA found significant differences between groups racialized as AA or NWH with respect to global ¹¹[C]-Pittsburgh Compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness values, p-tau181, and p-tau231 values (p < 0.05).

DISCUSSION

Racialization should be given more consideration in AD clinical research, particularly when biomarker results are used for inclusion or exclusion criteria for clinical trials and qualification in clinical practice.

Highlights

Global ¹¹[C]-Pittsburgh compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness, p-tau181, and p-tau231 differed between groups
Differences were unaffected by age, sex, apolipoprotein E *4 (APOE*4), education, and Mini-Mental State Examination (MMSE) score
Racialization needs more consideration in Alzheimer's disease clinical research
Additional work is needed to understand the sources of biomarker differences

Abstract Image

查看原文本刊更多论文

种族化对阿尔茨海默病神经影像学和血浆生物标志物的影响

鉴于成像和血浆生物标志物在阿尔茨海默病观察性研究和临床试验中的优势，了解这些生物标志物在不同种族群体之间的差异至关重要。方法对260名年龄在50 ~ 90岁（68.8±9.1岁）的非西班牙裔美国黑人（AA）和非西班牙裔美国白人（NHW）无痴呆的老年人进行血浆淀粉样蛋白-β (Aβ) 42/Aβ40、p-tau181、p-tau217、p-tau231、神经丝轻链（NfL）、使用Mann-Whitney U检验和协方差分析（ANCOVA）对胶质纤维酸性蛋白（GFAP）以及Aβ正电子发射断层扫描（PET）和磁共振（MR）成像衍生的皮质厚度进行分析。结果：Mann-Whitney试验和ANCOVA均发现AA组和NWH组在全球11[C]-匹兹堡化合物B （PiB）标准化摄取值比（SUVR）、皮质厚度值、p-tau181和p-tau231值方面存在显著差异(p <；0.05)。在阿尔茨海默病临床研究中应更多地考虑种族化，特别是当生物标志物结果用于临床试验和临床实践资格的纳入或排除标准时。Global 11[C]-Pittsburgh compound B （PiB）标准化摄取值比（SUVR）、皮质厚度、p-tau181和p-tau231在各组间的差异不受年龄、性别、载脂蛋白E*4 （APOE*4）、教育程度、在阿尔茨海默病的临床研究中，需要更多地考虑种族化，以了解生物标志物差异的来源，还需要进一步的工作

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.